Cargando…

Dynamics of Serum-Neutralizing Antibody Responses in Vaccinees through Multiple Doses of the BNT162b2 Vaccine

SARS-CoV-2 mRNA vaccines are administered as effective prophylactic measures for reducing virus transmission rates and disease severity. To enhance the durability of post-vaccination immunity and combat SARS-CoV-2 variants, boosters have been administered to two-dose vaccinees. However, long-term hu...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sheehan, Jared, Ardizzone, Caleb M., Khanna, Mayank, Trauth, Amber J., Hagensee, Michael E., Ramsay, Alistair J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10675463/ https://www.ncbi.nlm.nih.gov/pubmed/38006052 http://dx.doi.org/10.3390/vaccines11111720

Ejemplares similares

Longitudinal Variations in Antibody Responses against SARS-CoV-2 Spike Epitopes upon Serial Vaccinations
por: Yalcin, Dicle, et al.
Publicado: (2023)

Sensitivity of SARS-CoV-2 variant Delta to serum neutralization in BNT162b2 vaccinees and unvaccinated COVID-19 recovered cases
por: Alidjinou, Enagnon Kazali, et al.
Publicado: (2021)

Reduced neutralization of SARS-CoV-2 Omicron variant by BNT162b2 vaccinees’ sera: a preliminary evaluation
por: Mileto, D., et al.
Publicado: (2022)

Heterologous Booster with BNT162b2 Induced High Specific Antibody Levels in CoronaVac Vaccinees
por: Masson, Letícia Carrijo, et al.
Publicado: (2023)

Third-Dose BNT162b2 Vaccination Elicits Markedly High-Level SARS-CoV-2–Neutralizing Antibodies in Vaccinees Who Responded Poorly to a Second Dose in Japan
por: Amano, Masayuki, et al.
Publicado: (2022)

Neutralizing Activity of BNT162b2-Elicited Serum
por: Liu, Yang, et al.
Publicado: (2021)

Saliva and Plasma Neutralizing Activity Induced by the Administration of a Third bnt162b2 Vaccine Dose
por: Garziano, Micaela, et al.
Publicado: (2022)

Beyond neutralization for BNT162b2 mRNA vaccination
por: Damani-Yokota, Payal, et al.
Publicado: (2021)

Codominant IgG and IgA expression with minimal vaccine mRNA in milk of BNT162b2 vaccinees
por: Low, Jia Ming, et al.
Publicado: (2021)

Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees
por: Jäger, Michael, et al.
Publicado: (2022)

Long-Lasting T Cell Responses in BNT162b2 COVID-19 mRNA Vaccinees and COVID-19 Convalescent Patients
por: Hurme, Antti, et al.
Publicado: (2022)

Neutralizing Antibodies in COVID-19 Patients and Vaccine Recipients after Two Doses of BNT162b2
por: Favresse, Julien, et al.
Publicado: (2021)

SARS-CoV-2 Neutralization with BNT162b2 Vaccine Dose 3
por: Falsey, Ann R., et al.
Publicado: (2021)

Effect of vaccine dosing intervals on Omicron surrogate neutralization after three doses of BNT162b2
por: Prusinkiewicz, Martin A., et al.
Publicado: (2023)

Neutralizing Antibody Response of Vaccinees to SARS-CoV-2 Variants
por: Anichini, Gabriele, et al.
Publicado: (2021)

BNT162b2 and ChAdOx1 SARS-CoV-2 Post-vaccination Side-Effects Among Saudi Vaccinees
por: Alghamdi, Ahmed N., et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 variants by convalescent and BNT162b2 vaccinated serum
por: Bates, Timothy A., et al.
Publicado: (2021)

Evaluation of neutralizing antibodies after vaccine BNT162b2: Preliminary data
por: Vietri, Maria Teresa, et al.
Publicado: (2022)

Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population()
por: Kawasuji, Hitoshi, et al.
Publicado: (2022)

The BNT162b2 mRNA SARS-CoV-2 vaccine induces transient afucosylated IgG1 in naive but not in antigen-experienced vaccinees
por: Van Coillie, Julie, et al.
Publicado: (2022)

Neutralizing antibody titers to Omicron six months after vaccination with BNT162b2 in Colombia
por: Zapata-Cardona, María I., et al.
Publicado: (2022)

Omicron extensively but incompletely escapes Pfizer BNT162b2 neutralization
por: Cele, Sandile, et al.
Publicado: (2021)

Neutralization of SARS-CoV-2 Variants by Serum from BNT162b2 Vaccine Recipients
por: Valleriani, Fabrizia, et al.
Publicado: (2021)

Comparison of the kinetics and magnitude of antibody responses to different SARS-CoV-2 proteins in Sinopharm/BBIBP-CorV vaccinees following the BNT162b2 booster or natural infection
por: Jeewandara, Chandima, et al.
Publicado: (2022)

Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave
por: Yamamoto, Shohei, et al.
Publicado: (2023)

Antigenic Variation of the Dengue Virus 2 Genotypes Impacts the Neutralization Activity of Human Antibodies in Vaccinees
por: Martinez, David R., et al.
Publicado: (2020)

Long-Term Neutralizing Antibody Titers After BNT162b2 Vaccination in Hemodialysis Patients
por: Takazono, Takahiro, et al.
Publicado: (2023)

BNT162b2 induced neutralizing and non-neutralizing antibody functions against SARSCoV-2 diminish with age
por: Bates, Timothy A., et al.
Publicado: (2022)

Anti-RBD IgG antibodies and neutralizing antibody levels after the second BNT162b2 dose in patients with plasma cell disorders
por: Magen, Hila, et al.
Publicado: (2023)

Low neutralizing antibody responses in WM, CLL and NHL patients after the first dose of the BNT162b2 and AZD1222 vaccine
por: Gavriatopoulou, Maria, et al.
Publicado: (2021)

Could Prior COVID-19 Affect the Neutralizing Antibody after the Third BNT162b2 Booster Dose: A Longitudinal Study
por: Erdem, Mustafa Genco, et al.
Publicado: (2023)

Previously infected vaccinees broadly neutralize SARS-CoV-2 variants
por: Leier, Hans C., et al.
Publicado: (2021)

Reduced neutralizing antibody response in naïve Covishield vaccinees against Omicron emphasizes booster vaccination
por: Yadav, Pragya D., et al.
Publicado: (2022)

Neutralization of five SARS-CoV-2 variants of concern by convalescent and BBIBP-CorV vaccinee serum
por: Zhu, Yuqi, et al.
Publicado: (2022)

BNT162b2-induced neutralizing and non-neutralizing antibody functions against SARS-CoV-2 diminish with age
por: Bates, Timothy A., et al.
Publicado: (2022)

Neutralizing Response against Variants after SARS-CoV-2 Infection and One Dose of BNT162b2
por: Lustig, Yaniv, et al.
Publicado: (2021)

Neutralization and durability of 2 or 3 doses of the BNT162b2 vaccine against Omicron SARS-CoV-2
por: Xia, Hongjie, et al.
Publicado: (2022)

A heterologous AZD1222 priming and BNT162b2 boosting regimen more efficiently elicits neutralizing antibodies, but not memory T cells, than the homologous BNT162b2 regimen
por: Baek, Yae Jee, et al.
Publicado: (2023)

Pan-Sarbecovirus Neutralizing Antibodies in BNT162b2-Immunized SARS-CoV-1 Survivors
por: Tan, Chee-Wah, et al.
Publicado: (2021)

Neutralizing antibody response against variants of concern after vaccination of dialysis patients with BNT162b2
por: Speer, Claudius, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_6krs68ub1jnd5758n087l6nd86